Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Based on a review of recently published articles, we evaluated the current status of high-intensity focused ultrasound (HIFU) as a primary treatment option for localized prostate cancer and as a salvage therapy when radiation has failed. With mid-and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 90%, and an excellent morbidity profile, primary HIFU appears to be a valid alternative to active surveillance protocols in low-risk patients and standard therapies in patients with life expectancies of 10 or fewer years. Moreover, HIFU has a considerable potential for local-only recurrence after radiation failure. HIFU is a recent technology, and many improvements will undoubtedly expand its future indications and use for the management of prostate cancer.
- Sim HG, Cheng CW: Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834–845. CrossRef
- Grönberg H: Prostate cancer epidemiology. Lancet 2003, 361:859–864. CrossRef
- Boccon-Gibod LM, Dumonceau O, Toublang M, et al.: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005, 48:895–899. CrossRef
- Adolfsson J, Tribukait B, Levitt S: The 20-yr outcome in patients with well-or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumor ploidy and comorbidity. Eur Urol 2007, 52:1028–1035. CrossRef
- Wong YN, Mitra N, Hudes G, et al.: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683–2693. CrossRef
- Ter Haar G, Coussios C: High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 2007, 23:89–104. CrossRef
- Chapelon JY, Margonari J, Vernier F, et al.: In vivo effects of high-intensity ultrasound on prostate adenocarcinoma Dunning R3327. Cancer Res 1992, 52:6353–6357.
- Rouviere O, Lyonnet D, Raudrant A, et al.: MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001, 40:265–274. CrossRef
- Rouviere O, Souchon R, Salomir R, et al.: Transrectal high-intensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur J Radiol 2007, 63:317–327. CrossRef
- De Senneville BD, Mougenot C, Moonen CT: Real-time methods for treatment of mobile organs by MRI-controlled high-intensity focused ultrasound. Magn Reson Med 2007, 57:319–330. CrossRef
- Illing RO, Leslie TA, Kennedy JE, et al.: Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 2006, 98:1187–1192. CrossRef
- Ficarra V, Antoniolli SZ, Novara G, et al.: Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 2006, 98:1193–1198. CrossRef
- Uchida T, Ohkusa H, Nagata Y, et al.: Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006, 97:56–61. CrossRef
- Blana A, Walter B, Rogenhofer S, Wieland WF: High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004, 63:297–300. CrossRef
- Chaussy C, Thuroff S: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248–252. CrossRef
- Lee HM, Hong JH, Choi HY: High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:439–443. CrossRef
- Poissonnier L, Chapelon JY, Rouviere O, et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007, 51:381–387. CrossRef
- Vallancien G, Prapotnich D, Cathelineau X, et al.: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265–2267. CrossRef
- Thuroff S, Chaussy C, Vallancien G, et al.: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003, 17:673–677. CrossRef
- Uchida T, Ohkusa H, Yamashita H, et al.: Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006, 13:228–233. CrossRef
- Uchida T, Illing RO, Cathcart PJ, Emberton M: To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006, 98:537–539. CrossRef
- Uchida T, Rowland O, Cathcart PJ, Emberton M: The effect of neoadjuvant androgen suppression on prostate-related outcomes after high-intensity focused ultrasound. BJU Int 2006, 98:770–772. CrossRef
- Blana A, Murat FJ, Walter B, et al.: First analysis of the long-term results with transrectal HIFU in patients with localized prostate cancer. Eur Urol 2007, In press.
- Rebillard X, Davin JL, Soulie M, Comite de cancerologie de l’Association Francaise d’Urologie: Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 2003, 13:1428–1456.
- Madersbacher S, Pedevilla M, Vingers L, et al.: Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995, 55:3346–3351.
- Gelet A, Chapelon JY, Bouvier R, et al.: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996, 29:174–183.
- Chaussy C, Thuroff S: Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001, 15:437–440. CrossRef
- Ganzer R, Rogenhofer S, Walter B, et al.: PSA nadir is a significant predictor of treatment failure after high intensity focused ultrasound (HIFU) treatment of localized prostate cancer. Eur Urol, 2007, In press.
- Gelet A, Chapelon JY, Bouvier R, et al.: Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001, 40:124–129. CrossRef
- Chaussy C, Thuroff S: High-intensity focused ultrasound in localized prostate cancer. J Endourol 2000, 14:293–299. CrossRef
- Thuroff S, Chaussy C: High-intensity focused ultrasound: complications and adverse effects. Mol Urol 2000, 4:183–187.
- Chaussy C, Thuroff S, Rebillard X, Gelet A: Technology insight: high intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2005, 2:191–198. CrossRef
- Blana A, Rogenhofer S, Ganzer R, et al.: Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 2006, 24:585–590. CrossRef
- Pollack A, Hanlon AL, Horwitz EM, et al.: Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004, 171:1132–1136. CrossRef
- Shipley WU, Thames HD, Sandler HM, et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999, 281:1598–1604. CrossRef
- Zelefsky MJ, Kuban DA, Levy LB, et al.: Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2005, 62:327–333.
- Heinish M, Dirisamer A, Loidl W, et al.: Positron emission tomography/computed tomography with F-18-Fluorcholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml? Mol Imaging Biol 2006, 8:43–48. CrossRef
- Harisinghani MG, Barentsz J, Hahn PF, et al.: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491–2499. CrossRef
- Chaussy C, Thuroff S, Bergsdorf T: Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option [in German]. Urologe 2006, 45:1271–1275. CrossRef
- Murat FJ, Poissonnier L, Rouviere O, et al.: Salvage high intensity focused ultrasound (HIFU) treatment for recurrent prostate cancer after radiation therapy: High efficacy in patients with good initial prognosis [abstract 1777]. J Urol 2007, 177:591.
- Ross AB, Diederich CJ, Nau WH, et al.: Curvilinear transurethral ultrasound applicator for selective prostate thermal therapy. Med Phys 2005, 32:1555–1565. CrossRef
- Piel JE, Watkins RD, Gross P, et al.: A transrectal focused ultrasound probe for MR-guided ablation of the prostate. Proceedings of the 13th scientific meeting of the international society for magnetic resonance in medicine. Miami: International Society for Magnetic Resonance in Medicine; 2005.
- Paparel P, Curiel L, Chesnais S, et al.: Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005, 95:881–885. CrossRef
- Current status of high-intensity focused ultrasound for prostate cancer: Technology, clinical outcomes, and future
Current Urology Reports
Volume 9, Issue 2 , pp 113-121
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links